BML Capital Management LLC increased its position in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) by 20.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,643,907 shares of the biotechnology company's stock after purchasing an additional 457,716 shares during the period. Oramed Pharmaceuticals accounts for 4.0% of BML Capital Management LLC's portfolio, making the stock its 9th largest holding. BML Capital Management LLC owned 6.56% of Oramed Pharmaceuticals worth $6,398,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. World Equity Group Inc. purchased a new stake in Oramed Pharmaceuticals in the 4th quarter worth $48,000. XTX Topco Ltd boosted its stake in shares of Oramed Pharmaceuticals by 59.7% in the third quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company's stock worth $60,000 after acquiring an additional 9,242 shares during the period. Marquette Asset Management LLC purchased a new stake in shares of Oramed Pharmaceuticals during the fourth quarter worth about $81,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Oramed Pharmaceuticals during the 3rd quarter valued at approximately $272,000. Finally, Peapod Lane Capital LLC purchased a new position in Oramed Pharmaceuticals in the 4th quarter worth approximately $550,000. Hedge funds and other institutional investors own 12.73% of the company's stock.
Oramed Pharmaceuticals Price Performance
Shares of ORMP stock traded up $0.11 during trading hours on Tuesday, hitting $2.62. The stock had a trading volume of 240,078 shares, compared to its average volume of 161,207. The stock has a market capitalization of $105.62 million, a price-to-earnings ratio of 23.82 and a beta of 1.61. Oramed Pharmaceuticals Inc. has a one year low of $1.96 and a one year high of $3.14. The stock's 50-day moving average price is $2.30 and its two-hundred day moving average price is $2.35.
Analyst Ratings Changes
Separately, StockNews.com lowered shares of Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Wednesday, February 19th.
View Our Latest Analysis on ORMP
About Oramed Pharmaceuticals
(
Free Report)
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
Read More
Before you consider Oramed Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.
While Oramed Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
